TCR-MM is defined as being refractory to immunomodulatory agents, proteasome inhibitors, and anti-CD38 mAbs, representing an urgent unmet medical need with a median OS of 3-5 months(Pick M et al, Eur J Haem 2018; Gandhi U et al, ASH 2018). Sd has shown a 26.2% overall response rate (ORR) in 122 patients (pts) with TCR-MM in the Phase 2b STORM study (Chari A et al, ASH 2018). Here, we evaluate the OS of pts in the STORM study with Sd and in pts with bortezomib, carfilzomib, lenalidomide, pomalidomide, and daratumumab (“penta”)-exposed, TCR-MM from an observational cohort not receiving Sd.


The prognosis of TCR-MM in the real-world population appears very poor. Within the limits of this analysis, median OS of pts receiving Sd as their first therapy after their MM becomes TCR is significantly better than those not receiving Sd, suggesting that Sd may be associated with an OS benefit in pts with TCR-MM. 


Paul G. Richardson, Sundar Jagannath, Ajai Chari, Dan T. Vogl, Meletios A. Dimopoulos, Philippe Moreau, David Dingli, L J Wei, Lingling Li, Shijie Tang, William Reichman, Michael G. Kauffman, Jatin J. Shah, Sharon Shacham, Sagar Lonial; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Mount Sinai Medical Center, New York, NY; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY; Abramson Cancer Center, Philadelphia, PA; National and Kapodistrian University of Athens, Athens, Greece; CHU de Nantes-Hôtel Dieu, Nantes, France; Mayo Clinic, Rochester, MN; Harvard School of Public Health, Boston, MA; Karyopharm Therapeutics, Newton, MA; Karyopharm Therapeutics Inc, Newton, MA; Karyopharm Therapeutics Inc., Newton, MA; Winship Cancer Institute of Emory University, Atlanta, GA

Clinical trial information: NCT02336815

Abstract No: 

J Clin Oncol 37, 2019 (suppl; abstr 8014)


Paul Richardson, M.D. is the Clinical Program Leader and Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in Boston. He is also an Institute Physician and a RJ Corman Professor of Medicine, at Harvard Medical School in Cambridge, MA. In addition to multiple myeloma, his key clinical interests are regimen-related toxicity, stem cell transplantation, experimental therapies and cancer pharmacology, and more. Visit Dr. Paul Richardson’s full biography.

Previous Post
Safety and efficacy of once-weekly carfilzomib dosing in frail patients
Next Post
Efficacy of KRd with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.